TR200002298A3 - 1,2,4,5- Tetrahidro-Benzo [D] azepinler - Google Patents

1,2,4,5- Tetrahidro-Benzo [D] azepinler

Info

Publication number
TR200002298A3
TR200002298A3 TR2000/02298A TR200002298A TR200002298A3 TR 200002298 A3 TR200002298 A3 TR 200002298A3 TR 2000/02298 A TR2000/02298 A TR 2000/02298A TR 200002298 A TR200002298 A TR 200002298A TR 200002298 A3 TR200002298 A3 TR 200002298A3
Authority
TR
Turkey
Prior art keywords
azepines
benzo
tetrahydro
Prior art date
Application number
TR2000/02298A
Other languages
English (en)
Other versions
TR200002298A2 (tr
Inventor
Binggeli Alfred
Adam Geo
Maerki Hans-Peter
Wilhelm Maurice
Wostl Wolfgang
Mutel Vincent
Original Assignee
F.Hoffmann-La Roche Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F.Hoffmann-La Roche Ag filed Critical F.Hoffmann-La Roche Ag
Publication of TR200002298A2 publication Critical patent/TR200002298A2/tr
Publication of TR200002298A3 publication Critical patent/TR200002298A3/tr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Addiction (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Otolaryngology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
TR2000/02298A 1999-08-06 2000-08-04 1,2,4,5- Tetrahidro-Benzo [D] azepinler TR200002298A3 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP99115557 1999-08-06

Publications (2)

Publication Number Publication Date
TR200002298A2 TR200002298A2 (tr) 2001-03-21
TR200002298A3 true TR200002298A3 (tr) 2001-03-21

Family

ID=8238742

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2000/02298A TR200002298A3 (tr) 1999-08-06 2000-08-04 1,2,4,5- Tetrahidro-Benzo [D] azepinler

Country Status (27)

Country Link
US (1) US6218385B1 (tr)
JP (1) JP3260350B2 (tr)
KR (1) KR100390116B1 (tr)
CN (1) CN1146455C (tr)
AR (1) AR025035A1 (tr)
AT (1) ATE254614T1 (tr)
AU (1) AU774485B2 (tr)
BR (1) BR0003375A (tr)
CA (1) CA2314798A1 (tr)
CO (1) CO5180625A1 (tr)
DE (1) DE60006618T2 (tr)
ES (1) ES2209728T3 (tr)
HR (1) HRP20000520A2 (tr)
HU (1) HUP0003112A3 (tr)
ID (1) ID26743A (tr)
IL (1) IL137688A0 (tr)
MA (1) MA26748A1 (tr)
NO (1) NO20003966L (tr)
NZ (1) NZ506096A (tr)
PE (1) PE20010467A1 (tr)
PL (1) PL341890A1 (tr)
RU (1) RU2240317C2 (tr)
SG (1) SG93251A1 (tr)
TR (1) TR200002298A3 (tr)
UY (1) UY26276A1 (tr)
YU (1) YU49700A (tr)
ZA (1) ZA200003927B (tr)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60111568T2 (de) * 2000-12-22 2006-05-11 F. Hoffmann-La Roche Ag Tetrahydro-(benzo- oder thieno-)azepin-pyrazin und triazinderivative als mglur 1 antagonisten
US6953787B2 (en) 2002-04-12 2005-10-11 Arena Pharmaceuticals, Inc. 5HT2C receptor modulators
EP2133340B1 (en) * 2002-12-20 2013-01-16 Glaxo Group Limited Novel benzazepine derivatives
CN101792417A (zh) * 2003-06-17 2010-08-04 艾尼纳制药公司 用于治疗5ht2c受体相关疾病的苯并氮杂卓衍生物
SI2332921T1 (sl) * 2003-06-17 2016-06-30 Arena Pharmaceuticals, Inc. 8-kloro-1-metil-2,3,4,5-tetrahidro-1H-3-benzazapin hidroklorid
WO2005042491A1 (en) * 2003-10-22 2005-05-12 Arena Pharmaceuticals, Inc. Benzazepine derivatives and methods of prophylaxis or treatment of 5ht2c receptor associated diseases
WO2005042490A1 (en) * 2003-10-22 2005-05-12 Arena Pharmaceuticals, Inc. Benzazepine derivatives and methods of prophylaxis or treatment of 5ht2c receptor associated diseases
ES2332009T3 (es) 2004-12-21 2010-01-22 Arena Pharmaceuticals, Inc. Formas cristalinas de hidrocloruro de (r)-8-cloro-1-metil-2,3,4,5-tetrahidro-1h-3-benzazepina.
SI1833473T1 (sl) * 2004-12-23 2010-01-29 Arena Pharm Inc Sestavki modulatorjev 5HT2C receptorjev in postopki uporabe
CA2620333A1 (en) 2005-08-26 2007-03-01 Braincells, Inc. Neurogenesis by muscarinic receptor modulation
EP2258359A3 (en) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenesis by muscarinic receptor modulation with sabcomelin
EP2377530A3 (en) 2005-10-21 2012-06-20 Braincells, Inc. Modulation of neurogenesis by PDE inhibition
WO2007053596A1 (en) 2005-10-31 2007-05-10 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
CA2646044A1 (en) * 2006-04-03 2007-10-25 Arena Pharmaceuticals, Inc. Processes for the preparation of 8-chloro-1-methyl-2,3,4,5-tetrahydro-1h-3-benzazepine and intermediates related thereto
EP2026813A2 (en) 2006-05-09 2009-02-25 Braincells, Inc. 5 ht receptor mediated neurogenesis
JP2009536669A (ja) 2006-05-09 2009-10-15 ブレインセルス，インコーポレイティド アンジオテンシン調節による神経新生
EP1873527A1 (en) * 2006-06-30 2008-01-02 Schwarz Pharma Ag Method for identifying CRMP modulators
KR20090064418A (ko) 2006-09-08 2009-06-18 브레인셀즈 인코퍼레이션 4-아실아미노피리딘 유도체 포함 조합물
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
EP2578216A1 (en) 2006-11-22 2013-04-10 Seaside Therapeutics, Inc. Methods of treating fragile x syndrome
SG177128A1 (en) * 2006-12-05 2012-01-30 Arena Pharm Inc Processes for preparing (r)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1h-3-benzazepine and intermediates thereof
TW200845978A (en) * 2007-03-07 2008-12-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives
JP5491421B2 (ja) 2008-03-04 2014-05-14 アリーナ ファーマシューティカルズ， インコーポレイテッド ５−ｈｔ２ｃアゴニストである（ｒ）−８−クロロ−１−メチル−２，３，４，５−テトラヒドロ−１ｈ−３−ベンゾアゼピンに関連する中間体の調製のためのプロセス
US20100216805A1 (en) 2009-02-25 2010-08-26 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
EP2443080A2 (en) 2009-06-18 2012-04-25 Arena Pharmaceuticals, Inc. Process for the preparation of 5-ht2c receptor agonists
WO2011109398A2 (en) 2010-03-02 2011-09-09 President And Fellows Of Harvard College Methods and compositions for treatment of angelman syndrome and autism spectrum disorders
US20110294879A1 (en) 2010-05-28 2011-12-01 Xenoport, Inc. Method of treatment of fragile x syndrome, down's syndrome, autism and related disorders
KR20130112848A (ko) 2010-06-02 2013-10-14 아레나 파마슈티칼스, 인크. 5-ｈｔ2ｃ 수용체 아고니스트의 제조 방법
WO2012009646A1 (en) 2010-07-15 2012-01-19 Xenoport, Inc. Methods of treating fragile x syndrome, down's syndrome, autism and related disorders
EP3485878A1 (en) 2010-09-01 2019-05-22 Arena Pharmaceuticals, Inc. Modified-release dosage forms of 5-ht2c agonists useful for weight management
CN103189360A (zh) 2010-09-01 2013-07-03 艾尼纳制药公司 5-ht2c激动剂的非吸湿性盐
MX2013002422A (es) 2010-09-01 2013-05-17 Arena Pharm Inc Sales de lorcaserina con acidos opticamente activos.
SG188365A1 (en) 2010-09-01 2013-04-30 Arena Pharm Inc Administration of lorcaserin to individuals with renal impairment
AU2012392187B2 (en) 2012-10-09 2018-07-12 Arena Pharmaceuticals, Inc. Method of weight management

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4206210A (en) * 1977-01-19 1980-06-03 Smithkline Corporation Alkylthio-7,8-dihdroxy-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepines having dopaminergic activity
ES2074867T3 (es) * 1990-11-06 1995-09-16 Pfizer Derivados de quinazolina para potenciar la actividad antitumoral.
US5241065A (en) * 1992-02-25 1993-08-31 Schering Corporation 2,3,4,5-tetrahydro-1h-3-benzazepines having anti-psychotic activity

Also Published As

Publication number Publication date
HUP0003112A3 (en) 2003-07-28
CN1283623A (zh) 2001-02-14
ZA200003927B (en) 2001-02-06
MA26748A1 (fr) 2004-12-20
RU2240317C2 (ru) 2004-11-20
AU774485B2 (en) 2004-07-01
JP3260350B2 (ja) 2002-02-25
DE60006618T2 (de) 2004-09-23
AR025035A1 (es) 2002-11-06
HUP0003112A2 (hu) 2002-11-28
TR200002298A2 (tr) 2001-03-21
IL137688A0 (en) 2001-10-31
NO20003966D0 (no) 2000-08-04
DE60006618D1 (de) 2003-12-24
KR100390116B1 (ko) 2003-07-04
SG93251A1 (en) 2002-12-17
ID26743A (id) 2001-02-08
PE20010467A1 (es) 2001-04-17
ATE254614T1 (de) 2003-12-15
UY26276A1 (es) 2000-10-31
KR20010082510A (ko) 2001-08-30
NO20003966L (no) 2001-02-07
PL341890A1 (en) 2001-02-12
CO5180625A1 (es) 2002-07-30
NZ506096A (en) 2002-08-28
HU0003112D0 (en) 2000-10-28
JP2001089472A (ja) 2001-04-03
ES2209728T3 (es) 2004-07-01
CA2314798A1 (en) 2001-02-06
CN1146455C (zh) 2004-04-21
HRP20000520A2 (en) 2001-06-30
US6218385B1 (en) 2001-04-17
YU49700A (sh) 2003-04-30
AU4897900A (en) 2001-02-08
BR0003375A (pt) 2001-03-13

Similar Documents

Publication Publication Date Title
TR200002298A3 (tr) 1,2,4,5- Tetrahidro-Benzo [D] azepinler
MA26831A1 (fr) Derives de benzodiazepine."
HK1051037A1 (en) Benzodiazepine derivatives.
ATE269694T1 (de) Oxcarbazepinsuspension
DK1237904T3 (da) 14,15-beta-methylensubstituerede androgener
MXPA02005070A (es) 1-benzazepinas sustituidas y derivados de las mismas.
AU2001264097A1 (en) 1, 2, 3, 5 -tetrahydrobenzo`c!azepin-4-one derivatives having muscarinic antagonist activity
HUP9902291A2 (hu) Új 2,3-benzodiazepin-származékok
NO20015397L (no) 1,5-Benzodiazepin-derivater
DE69704297T2 (de) 10,11-Dihydro-10-oxo-5H-dibenz[b,f]azepin-5-carboxamidderivate
AU2656100A (en) Clothes hanger
GB9823972D0 (en) Hosiery
GB9907234D0 (en) Drug assay
GB2350361B (en) 3,4,5-tricyanophenyl derivatives
GB9910366D0 (en) 1,5-Benzodiazepine Derivatives
ES1042496Y (es) "pilona sumible".
ZA200107384B (en) Spinneret.
AU6455300A (en) Clothes hanger
EG23327A (en) Metraplant "iucd".
HK1043992A1 (zh) 2，1-苯並異噻唑啉2，2-二氧化物
IL165436A0 (en) 7,10-bis-trichlotoacetyl-10 deactylbaccatin III
HUP0203381A3 (en) 5-halo-4-fluoro-4,7,7-trimethyl-3-oxabicyclo[4.1.0]heptane-2-on
FI980405A0 (fi) Industriellt, kontinuerligt foerfarande foer framstaellning av "gravkalk"
GB9917367D0 (en) Sock
BR1100649A (pt) Derivados de 10,11-metano dibenzo suberano